semaglutide cardiovascular outcomes news 2025 Improves in Patients With History of Coronary Artery Bypass Graft and Obesity SELECT Trial

The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has approved a semaglutide injection (Wegovy) to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis

The review urges nurse practitioners to balance expanding clinical promise with careful prescribing, patient education, monitoring, access advocacy, and vigilance for gastrointestinal, endocrine, pregnancy-related, and rare serious risks.

Its designed to complement the benefits of GLP-1 medications while reducing the discomfort they can cause

Wegovy (Semaglutide) is an FDA-approved, once-weekly injectable medication for chronic weight management in adults with obesity or overweight conditions